Case reports in oncology · 2025
Successful Treatment of BRAF-Mutated Metastatic Melanoma in an Advanced-Age Patient with Dabrafenib and Trametinib: A Case Report and Literature Review.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Cheol-Sik, Kim Jae-Joon, Oh Sang-Bo
Аннотация
INTRODUCTION: BRAF and MEK inhibitors, specifically dabrafenib and trametinib, have substantially improved treatment outcomes in metastatic melanoma. However, their use in advanced-age patients remains insufficiently studied.
CASE PRESENTATION: A 90-year-old man with a history of wide excision for cutaneous melanoma developed liver metastases. Core needle biopsy confirmed the presence of a BRAF V600E mutation. The patient was treated with dabrafenib (150 mg twice daily) and trametinib (2 mg once daily). After 6 months, he achieved complete remission of liver metastases, experiencing only mild adverse events, including grade 1 pyrexia and diarrhea.
CONCLUSION: This case report demonstrates that dabrafenib-trametinib combination therapy is an effective and well-tolerated treatment option for BRAF-mutated metastatic melanoma in advanced-age patients.
CASE PRESENTATION: A 90-year-old man with a history of wide excision for cutaneous melanoma developed liver metastases. Core needle biopsy confirmed the presence of a BRAF V600E mutation. The patient was treated with dabrafenib (150 mg twice daily) and trametinib (2 mg once daily). After 6 months, he achieved complete remission of liver metastases, experiencing only mild adverse events, including grade 1 pyrexia and diarrhea.
CONCLUSION: This case report demonstrates that dabrafenib-trametinib combination therapy is an effective and well-tolerated treatment option for BRAF-mutated metastatic melanoma in advanced-age patients.